Prot #CA209025: A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

Project: Research project

Project Details

StatusActive
Effective start/end date1/20/131/20/22

Funding

  • Bristol-Myers Squibb Company (Prot #CA209025)